The PharmAccess Leaders Forum is Europe’s most respected event for stakeholders involved in achieving patient access for innovative medications. Experience 2 days of networking, partnering and engaging Europe’s top stakeholders to achieve enhanced market access and better demonstrate your product’s value to payers.

Download agenda here for complete speaker list

Payers & HTA Agencies

Head of Pharmaceuticals Department
G-BA (Federal Joint Committee), Germany

Associate Director, NICE Office for Market Access
National Institute for Health and Care Excellence, UK

Coordinator, Internal HTA experts, Chair, the Domain Task Force ‘Joined HTA’, the BeNeLuxA Initiative
National Institute for Health and Disability Insurance (RIZIV INAMI), Belgium

Member, and former interim Chief Clinical Officer
NHS Thurrock Clinical Commissioning Group, UK

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics University of Groningen, The Netherlands

Head of Section Health Economics
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Associate Professor, Economic Evaluations in Health Care
Institute of Health Policy & Management (iBMG)
Institute for Medical Technology Assessment (iMTA)
Erasmus University Rotterdam, Netherlands

General Director, Center of Healthcare Quality Assessment and Control
Ministry of Health, Russia
 

Industry Experts

Senior Vice President, Global Marketing and Strategy
EMD Serono, USA

Vice President, Head of Operations and Payer Intelligence Global Market Access
Sanofi, UK

Head of Market Access
Mundipharma International, UK

Senior Director, Value Evidence Leader, Immuno-inflammation
Value Evidence & Outcomes (VEO)
GSK, UK

Director Health Technology Assessment & Outcomes Research Health & Value
Pfizer, Germany

Head, Market Access & Pricing Rare Diseases, R&D Rare Disease Unit
GlaxoSmithKline, UK

Senior Director, Access and Operations EU & RoW
Santhera, Switzerland

Value & Access Director
Amgen, Italy

Pricing and Market Access Lead
AstraZeneca, UK

Health Economics and Outcomes Research Leader
Mundipharma International, UK

Health Economics, Market Access and Reimbursement Lead
Janssen-Cilag, UK

 

Policy Researchers

Professor of Health Economics
MIUR - Italian Ministry of Research and Education

Senior Researcher
Karolinska Institute, Sweden

Director Of Research
Tufts Center for the Study of Drug Development
Tufts University School of Medicine, USA

 

Download agenda here for complete speaker list

Pictures from recent PharmAccess Leaders Forums. Imagine being there...

“Payers” (health plans, sick funds & insurers, payers, health technology assessors, hospital financial management & health department officials) in almost all circumstances, in both developed and developing countries are under extreme budgetary pressure. Many health systems in the developed world, face ageing populations, economic crisis and rapidly increasing healthcare costs in general, including the sustained cost increases of innovative and novel drugs. This is forcing payers to make difficult choices regarding which medical procedures & medications to fund and reimburse. No longer are “me too” drugs that have achieved regulatory approval simply approved for reimbursement at high prices. Payers need to make tough decisions based on what they define as “value”, unfortunately sometimes at the expense of funding treatments in some “lower priority” disease indications or individual patients. Despite intense political pressure from patients and stakeholders who believe healthcare is an inalienable “right” and should be “free for all,” the reality is that payers have a finite and limited budget, and face a high degree of risk in decision making. They operate within an environment where a multitude of products are on offer, each making various therapeutic claims of efficacy and safety, often with insufficient data to validate supposed health outcome improvements over existing treatment options. How can payers make the right decision in a high-risk, high uncertainty environment?

Various options and decision-making tools exist, some old, some novel. Traditional decision making based on, for example, price referencing, DRGs budgets or generic substitution are still significant. However, recent advances in the sophistication of HTA analysis and modeling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.

Why this meeting?

This meeting will provide an ideal opportunity for “payers” and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies an invaluable insight into the decision-making processes and approaches of these vital stakeholders. Attendees will be able to understand and develop best practice approaches to such vital and common challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.

Speaker List - Day 1

Head of Pharmaceuticals Department
G-BA (Federal Joint Committee), Germany

Member, and former interim Chief Clinical Officer
NHS Thurrock Clinical Commissioning Group, UK

General Director, Center of Healthcare Quality Assessment and Control
Ministry of Health, Russia

Head of Market Access
Mundipharma International, UK

Associate Director, NICE Office for Market Access
National Institute for Health and Care Excellence, UK

Coordinator, Internal HTA experts, Chair, the Domain Task Force ‘Joined HTA’, the BeNeLuxA Initiative
National Institute for Health and Disability Insurance (RIZIV INAMI), Belgium

Member, Joint Committee Vaccination & Immunisation (JCVI) London, UK
Prof. of Pharmacoeconomics University of Groningen, The Netherlands

Vice President, Head of Operations and Payer Intelligence
Global Market Access
Sanofi, UK

Senior Researcher
Karolinska Institute, Sweden

Pricing and Market Access Lead
AstraZeneca, UK

Head of Section Health Economics
Amgros, Pharmaceutical Procurement Service for Regional Authorities, Denmark

Professor of Health Economics
MIUR - Italian Ministry of Research and Education

Director Health Technology Assessment & Outcomes Research Health & Value
Pfizer, Germany

Associate Professor, Economic Evaluations in Health Care
Institute of Health Policy & Management (iBMG)
Institute for Medical Technology Assessment (iMTA)
Erasmus University Rotterdam, Netherlands

Senior Vice President, Global Marketing and Strategy
EMD Serono, USA

Health Economics and Outcomes Research Leader
Mundipharma International, UK

Director Of Research
Tufts Center for the Study of Drug Development
Tufts University School of Medicine, USA

Flexible pricing and reimbursement schemes, have been in existence for around a decade in Europe and places like Canada, and is starting to become popular in the USA. They are known by many other names including Managed Entry Agreements (MEAs), Value-Based Pricing, Pay for Performance or Outcomes-based schemes. Most agreements so far, in reality, have been more basic financial-based arrangements (such as budget-capping and refunds for payers), rather than more sophisticated value-based models, based on improved health outcomes. As ‘’patient-centricity” becomes more of a focus for pharmaceutical companies and payers alike, most would agree that in principle, paying for outcomes is ideal and a “win-win” for all stakeholders, especially the patient. In theory, this helps payers conditionally approve the reimbursement of an innovative, yet expensive therapy and allow patient access without delay. Quality evidence is very much lacking at the time of launch, so the “wait and see approach” that risk sharing can provide, can be a great compromise for the industry, payers and patients. Payers can also avoid wastage when drugs are unsuccessful, but only paying for positive outcomes. The pharmaceutical industry can benefit, by maintaining a higher list price to avoid the negative price spiral due to reference pricing. They can also benefit from early-access. There have been also some high-profile value-based pricing schemes in the USA, which will pay for outcomes and look very innovative and promising. On both sides of the Atlantic, innovative agreements are here to stay. However, implementing complex outcomes-based schemes in practice is very challenging. It is difficult enough to measure outcomes across a patient population, let alone individual patients. Electronic Medical Records are still not widespread or integrated enough to provide sufficient real-world data, so busy doctors have to still keep records the manual way, which are prone to error. This stream will clarify the process of establishing, preparing, implementing and delivering a successful risk-sharing / managed entry agreement s, outcome based and value-based schemes, to improve the access of innovative medicines for patients.

Speaker List - Stream 1

Vice President, Head of Operations and Payer Intelligence Global Market Access
Sanofi, UK

Senior Researcher
Karolinska Institute, Sweden

Pricing and Market Access Lead
AstraZeneca, UK

Health Economics, Market Access and Reimbursement Lead
Janssen-Cilag, UK

Senior Director, European Regional Health and Value Lead
Pfizer, UK

 Value & Access Director
Amgen, Italy

Senior Director, Access and Operations EU & RoW
Santhera, Switzerland

Head, Market Access & Pricing Rare Diseases, R&D Rare Disease Unit
GlaxoSmithKline, UK

 

This stream will feature best practice case studies of designing, collecting & presenting HEOR studies and economic models of products’ therapeutic and economic benefits.
The intent is to allow participants to both enhance internal decision-making and value-demonstration to external stakeholders. Methodological robustness, realistic assumptions and local-level customisation will be discussed as well as the extent of data depth and breadth which HTAs, Payers & Hospitals require from their perspective to make the right reimbursement decision. MCDA and benchmarking with accepted payer models will also be discussed to increase transparency and the understanding of the likelihood of a positive reimbursement or assessment outcome.

Speaker List - Stream 2

Senior Vice President, Global Marketing and Strategy
EMD Serono, USA

Senior Director, Value Evidence Leader, Immuno-inflammation Value Evidence & Outcomes (VEO)
GSK, UK

Coordinator, Internal HTA experts, Chair, the Domain Task Force ‘Joined HTA’, the BeNeLuxA Initiative
National Institute for Health and Disability Insurance (RIZIV INAMI), Belgium

Health Economics and Outcomes Research Leader
Mundipharma International, UK

Director Health Technology Assessment & Outcomes Research Health & Value
Pfizer, Germany

Director Of Research
Tufts Center for the Study of Drug Development
Tufts University School of Medicine, USA

Professor of Health Economics
MIUR - Italian Ministry of Research and Education

 

This event will provide all delegates the chance to meet one another through our many networking opportunities. With pre-event, mid-morning and mid-afternoon breaks as a standard, this event will also feature a complimentary networking dinner for all participants.

This evening will allow you to meet with our expert speaker panel who represent many stakeholder groups in a less formal setting. Our networking lunches will also allow you plenty of time to meet with your peers and colleagues whilst you refuel through the event.

Payers, HTAs & Policy Makers:
Senior representatives from Payers, health plans & insurers, Public health experts, health technology assessors, hospital financial management, government & health ministry officials, health management and managed care organizations, epidemiology, horizon scanning, scientific advice, pharmacy strategy & budget management.

Industry: Corporate senior management, vice presidents, directors, senior managers in:
Market access, health economics, pricing & reimbursement, health outcomes, government & regulatory affairs as well as those focused on designing studies to achieve value-adding endpoints, such as R&D strategy, clinical development and medical affairs.

Other Stakeholders:
Regulatory agencies, key-opinion leaders, independent health economists, health researchers and academics, physicians, patient groups, consultants & solution providers.

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Event Partners

Share with Colleagues